Cefotaxime
- Generic Name
- Cefotaxime
- Brand Names
- Claforan
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N5O7S2
- CAS Number
- 63527-52-6
- Unique Ingredient Identifier
- N2GI8B1GK7
- Background
Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
- Indication
Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
- Associated Conditions
- Bone and Joint Infections caused by susceptible Bacterial Infections, Central Nervous System Infections caused by susceptible Bacterial Infections, Genitourinary tract infection caused by susceptible Bacterial Infections, Gynaecological infection caused by susceptible bacteria, Intraabdominal Infections caused by susceptible Bacterial Infections, Lower Respiratory Tract Infection (LRTI) caused by susceptible bacteria, Postoperative Wound Infection, Septicemia caused by susceptible Bacterial Infections, Skin and skin-structure infections caused by susceptible bacteria
Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis
- Conditions
- Cirrhosis
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 96
- Registration Number
- NCT01820026
- Locations
- 🇮🇹
Manuela Merli, Rome, Italy
Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
- First Posted Date
- 2011-08-31
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Target Recruit Count
- 2032
- Registration Number
- NCT01426191
Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LC
- Conditions
- SBPLiver Cirrhosis
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Korea University
- Target Recruit Count
- 261
- Registration Number
- NCT01265173
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
Cerebral Antibiotics Distribution After Acute Brain Injury
- Conditions
- Bacterial InfectionBrain Injury
- Interventions
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT01059890
- Locations
- 🇫🇷
Poitiers University Hospital - 2 rue de la Milétrie - Réanimation chirugicale, Poitiers, France
Study of Conservative Versus Surgical Treatment of Appendicitis
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2009-04-21
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 360
- Registration Number
- NCT00469430
- Locations
- 🇸🇪
Göteborg University, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden
Effect of, OAT3, on the Renal Secretion of Cefotaxime
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT00187655
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.